Laura M. Freedman, MD
The use of post-mastectomy radiation has historically been a controversial topic in patients with 1 to 3 positive lymph nodes, according to Laura M. Freedman, MD. Revisions to the National Comprehensive Cancer Network (NCCN) guidelines have, however, have now allowed physicians to pinpoint the women who are most likely to benefit from the treatment.
State of the Science Summit™ on Breast Cancer, Freedman, assistant professor, director of radiation oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discussed the impact of the updated NCCN guidelines on clinical applications of radiation therapy in patients with breast cancer.
OncLive®: Can you discuss the state of radiation oncology in breast cancer, which you focused on in your presentation?
: There are many updates in radiation oncology that came from the 2017 San Antonio Breast Cancer Symposium. First, I wanted all from the medical, surgical, and radiation oncology communities to be aware of the updated guidelines for post-mastectomy radiation given in women who have pathologic T1/T2 tumors and 1 to 3 positive nodes. The guidelines have allowed us to assess the risk-benefit ratio and guide our patients in the decision-making process.
... to read the full story